Pay in 4 interest-free payments of $10.50 Learn more
Ships within 48 hours · Estimated delivery Aug 5 - Aug 10
and matrix metalloproteinase activities of CRC cell lines
LY-3090314 enhances the efficacy of cisplatin and carboplatin in solid tumor cancer cell lines in vitro
on the production of inflammatory mediators by rheumatoid synovial fibroblasts
The AUC is good in dogs and rats
12 cells (EC50 ~ 4 nM) and RS4
PAI-039 - CAS# 393105-53-8 size:2mg solid and matrix metalloproteinase activities ofPAI 039, CAS No. 393105 53 8, is a novel plasminogen activator inhibitor 1 (PAI 1) inhibitor. The pharmacokinetic profile of PAI 039 indicated an oral bioavailability of 43 + 15. 3% and a plasma half life of 6. 2 + 1. 3 h. PAI 039 is an orally active prothrombolytic drug that inhibits PAI 1 and accelerates fibrinolysis while maintaining normal coagulation in a model of coronary occlusion . PAI 039 exerts antithrombotic efficacy in rat models of
US$ 500.97
US$ 568.48
US$ 16.66